The somatic mutational processes that occur within human cancers generate novel, non-self proteins that have the potential to be detected by antibodies and therefore exploited therapeutically. Such antibodies can be generated through the stimulation of the immune system or through the synthetic generation of monoclonal antibodies (mAbs). The nascent ability to determine the complete transcriptomes […]
Read More